Table 1.
BRACE trial participants in the BCOS sub-study in Australia with pre and post vaccination samples included in the paired analysis.
| Serology |
Whole blood stimulation |
||||
|---|---|---|---|---|---|
| ChAdOx1-S V0 & V1 n = 65 | ChAdOx1-S V0 & V2 n = 67 | BNT162b2 V0 & V2 n = 55 | ChAdOx1-S V0 & V1 n = 59 | BNT162b2 V0 & V2 n = 19 | |
| Age (years) at 1st COVID-19 vaccination dose, median (IQR) | |||||
| 51 (39–58) | 51 (40–59) | 47 (37–56) | 49 (39–58) | 43 (33–50) | |
| Sex | |||||
| Male | 14 (21.5%) | 18 (26.9%) | 12 (21.8%) | 12 (20.3%) | 3 (15.8%) |
| Female | 51 (78.5%) | 49 (73.1%) | 43 (78.2%) | 47 (79.7%) | 16 (84.2%) |
| Any COVID-19 comorbiditiesa | |||||
| Yes | 9 (13.8%) | 13 (19.4%) | 13 (23.6%) | 10 (16.9%) | 5 (26.3%) |
| Diabetes | 1 (1.5%) | 0 | 0 | 1 (1.7%) | 0 |
| Cardiovascular disease | 7 (10.8%) | 9 (13.4%) | 8 (14.5%) | 7 (11.9%) | 3 (15.8%) |
| Chronic respiratory disease | 1 (1.5%) | 5 (7.5%) | 5 (9.1%) | 2 (3.4%) | 2 (10.5%) |
| No | 56 (86.2%) | 54 (80.6%) | 42 (76.4%) | 49 (83.1%) | 14 (73.7%) |
| Obesity | |||||
| Yes | 10 (15.4%) | 12 (17.9%) | 8 (14.5%) | 10 (16.9%) | 4 (21.1%) |
| No | 50 (76.9%) | 51 (76.1%) | 42 (76.4%) | 45 (76.3%) | 15 (78.9%) |
| Missing | 5 (7.7%) | 4 (6.0%) | 5 (9.1%) | 4 (6.8%) | 0 |
| Smoking | |||||
| Yes | 4 (6.2%) | 3 (4.5%) | 3 (5.5%) | 5 (8.5%) | 0 |
| No | 61 (93.8%) | 64 (95.5%) | 52 (94.5%) | 54 (91.5%) | 19 (100.0%) |
| Occupation | |||||
| Allied health | 3 (4.6%) | 2 (3.0%) | 2 (3.6%) | 2 (3.4%) | 1 (5.3%) |
| Clerical/Administrative | 7 (10.8%) | 7 (10.4%) | 3 (5.5%) | 6 (10.2%) | 2 (10.5%) |
| Doctor | 8 (12.3%) | 11 (16.4%) | 4 (7.3%) | 6 (10.2%) | 12 (63.2%) |
| Nurse/Midwife | 25 (38.5%) | 22 (32.8%) | 32 (58.2%) | 25 (42.4%) | 4 (21.1%) |
| Other role | 22 (33.8%) | 25 (37.3%) | 13 (23.6%) | 20 (33.9%) | 0 |
| Patient service assistant | 0 | 0 | 1 (1.8%) | 0 | 0 |
| BCG-vaccinated prior to BRACE trial | |||||
| No | 30 (46.2%) | 28 (41.8%) | 24 (43.6%) | 27 (45.8%) | 10 (52.6%) |
| Yes | 35 (53.8%) | 39 (58.2%) | 31 (56.4%) | 32 (54.2%) | 9 (47.4%) |
| BCG-vaccinated in BRACE trial | |||||
| No | 18 (27.7%) | 18 (26.9%) | 20 (36.4%) | 17 (28.8%) | 7 (36.8%) |
| Yes | 47 (72.3%) | 49 (73.1%) | 35 (63.6%) | 42 (71.2%) | 12 (63.2%) |
| Any other vaccinations between V0 and post COVID-19 vaccination blood | |||||
| Yes | 3 (4.6%) | 9 (13.4%) | 9 (16.4%) | 3 (5.1%) | 1 (5.3%) |
| Age (years) at 1st COVID-19 vaccination dose, median (IQR) | |||||
| 51 (39–58) | 51 (40–59) | 47 (37–56) | 49 (39–58) | 43 (33–50) | |
| Days between 1st and 2nd COVID-19 vaccination doses, median (IQR) | |||||
| 87 (84–91) | 87 (84–91) | 22 (21–25) | 87 (84–91) | 22 (21–27) | |
| Days between COVID-19 vaccination dose and post blood, median (IQR) | |||||
| Dose 1 and V1 | 28 (27–28) | – | – | 28 (27–28) | – |
| Dose 2 and V2 | – | 28 (28–28) | 28 (28–28) | – | 28 (27–28) |
| Days between pre blood (V0) and post blood, median (IQR) | |||||
| 29 (28–32) | 119 (113–126) | 53 (50–57) | 29 (28–32) | 51 (49–56) | |
a
At BRACE trial randomisation: Diabetes (any type), cardiovascular disease (including hypertension) or chronic respiratory disease (including asthma and chronic obstructive pulmonary disease).